Reactivation Tuberculosis in a Patient With Anti–TNF-α Treatment
- 1 May 2001
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 96 (5) , 1665-1666
- https://doi.org/10.1111/j.1572-0241.2001.03836.x
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- The relationship between infliximab treatment and lymphoma in Crohn's diseaseGastroenterology, 1999
- Review article: safety of infliximab in clinical trialsAlimentary Pharmacology & Therapeutics, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trialGastroenterology, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.The Journal of Immunology, 1997
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Diagnostic Standards and Classification of TuberculosisAmerican Review of Respiratory Disease, 1990